SWM
ONCY

SeaCrest Wealth Management’s Oncolytics Biotech ONCY Stock Holding History

SeaCrest Wealth Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,000
Closed -$27.2K – 630
2026
Q1 		$27.2K Hold
32,000
– – ﹤0.01% 631
2025
Q4 		$30.7K Hold
32,000
– – ﹤0.01% 630
2025
Q3 		$41K Hold
32,000
– – ﹤0.01% 624
2025
Q2 		$24.7K Hold
32,000
– – ﹤0.01% 614
2025
Q1 		$17.6K Buy
32,000
+6,000
+23% +$4.39K ﹤0.01% 653
2024
Q4 		$23.8K Hold
26,000
– – ﹤0.01% 652
2024
Q3 		$22.6K Buy
+26,000
New +$25.5K ﹤0.01% 647

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.71B AUM 30.33% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

SeaCrest Wealth Management's ONCY Position: Q2 2026 in Review

SeaCrest Wealth Management sold out of Oncolytics Biotech (ONCY) in Q2 2026, closing a stake of 32,000 shares — an estimated $27.2K sold.

SeaCrest Wealth Management first reported a position in ONCY in Q3 2024 and held it in 7 quarters. The position peaked at $41K in Q3 2025. 24 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • SeaCrest Wealth Management reported no remaining Oncolytics Biotech position as of Q2 2026 after selling out during the quarter.
  • SeaCrest Wealth Management sold 32,000 Oncolytics Biotech shares in Q2 2026, an estimated $27.2K.
  • SeaCrest Wealth Management first reported a position in Oncolytics Biotech in Q3 2024 and held it in 7 quarters.
  • SeaCrest Wealth Management's Oncolytics Biotech position peaked at $41K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.